123 related articles for article (PubMed ID: 19875043)
1. Synthesis and evaluation of a radioiodinated lumiracoxib derivative for the imaging of cyclooxygenase-2 expression.
Kuge Y; Obokata N; Kimura H; Katada Y; Temma T; Sugimoto Y; Aita K; Seki K; Tamaki N; Saji H
Nucl Med Biol; 2009 Nov; 36(8):869-76. PubMed ID: 19875043
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of radioiodinated cyclooxygenase-2 inhibitors as potential SPECT tracers for cyclooxygenase-2 expression.
Kuge Y; Katada Y; Shimonaka S; Temma T; Kimura H; Kiyono Y; Yokota C; Minematsu K; Seki K; Tamaki N; Ohkura K; Saji H
Nucl Med Biol; 2006 Jan; 33(1):21-7. PubMed ID: 16459255
[TBL] [Abstract][Full Text] [Related]
3. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2.
Esser R; Berry C; Du Z; Dawson J; Fox A; Fujimoto RA; Haston W; Kimble EF; Koehler J; Peppard J; Quadros E; Quintavalla J; Toscano K; Urban L; van Duzer J; Zhang X; Zhou S; Marshall PJ
Br J Pharmacol; 2005 Feb; 144(4):538-50. PubMed ID: 15655513
[TBL] [Abstract][Full Text] [Related]
4. Impact of structural alterations on the radiopharmacological profile of
Tietz O; Marshall A; Bergman C; Wuest M; Wuest F
Nucl Med Biol; 2018; 62-63():9-17. PubMed ID: 29800798
[TBL] [Abstract][Full Text] [Related]
5. Characterization of eltenac and novel COX-2 selective thiopheneacetic acid analogues in vitro and in vivo.
Klein T; Dullweber F; Brehm C; Prinz W; Baudler M; Figala V; Herrmann M
Biochem Pharmacol; 2008 Sep; 76(6):717-25. PubMed ID: 18674517
[TBL] [Abstract][Full Text] [Related]
6. Molecular determinants for the selective inhibition of cyclooxygenase-2 by lumiracoxib.
Blobaum AL; Marnett LJ
J Biol Chem; 2007 Jun; 282(22):16379-90. PubMed ID: 17434872
[TBL] [Abstract][Full Text] [Related]
7. Designing multitarget anti-inflammatory agents: chemical modulation of the lumiracoxib structure toward dual thromboxane antagonists-COX-2 inhibitors.
Bertinaria M; Shaikh MA; Buccellati C; Cena C; Rolando B; Lazzarato L; Fruttero R; Gasco A; Hoxha M; Capra V; Sala A; Rovati GE
ChemMedChem; 2012 Sep; 7(9):1647-60. PubMed ID: 22865828
[TBL] [Abstract][Full Text] [Related]
8. Exploring the molecular determinants of substrate-selective inhibition of cyclooxygenase-2 by lumiracoxib.
Windsor MA; Valk PL; Xu S; Banerjee S; Marnett LJ
Bioorg Med Chem Lett; 2013 Nov; 23(21):5860-4. PubMed ID: 24060487
[TBL] [Abstract][Full Text] [Related]
9. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I
J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and in vivo evaluation of 18F-desbromo-DuP-697 as a PET tracer for cyclooxygenase-2 expression.
de Vries EF; van Waarde A; Buursma AR; Vaalburg W
J Nucl Med; 2003 Oct; 44(10):1700-6. PubMed ID: 14530489
[TBL] [Abstract][Full Text] [Related]
11. A validated high-performance liquid chromatographic assay for determination of lumiracoxib in human plasma.
Cheremina O; Brune K; Hinz B
Biomed Chromatogr; 2006 Oct; 20(10):1033-7. PubMed ID: 16602135
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of [(11)C]rofecoxib as PET tracer for cyclooxygenase 2 overexpression in rat models of inflammation.
de Vries EF; Doorduin J; Dierckx RA; van Waarde A
Nucl Med Biol; 2008 Jan; 35(1):35-42. PubMed ID: 18158941
[TBL] [Abstract][Full Text] [Related]
13. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
[TBL] [Abstract][Full Text] [Related]
14. Radiosynthesis of a ¹⁸F-labeled 2,3-diarylsubstituted indole via McMurry coupling for functional characterization of cyclooxygenase-2 (COX-2) in vitro and in vivo.
Kniess T; Laube M; Bergmann R; Sehn F; Graf F; Steinbach J; Wuest F; Pietzsch J
Bioorg Med Chem; 2012 Jun; 20(11):3410-21. PubMed ID: 22560838
[TBL] [Abstract][Full Text] [Related]
15. Radiosynthesis, in vitro validation, and in vivo evaluation of 18F-labeled COX-1 and COX-2 inhibitors.
McCarthy TJ; Sheriff AU; Graneto MJ; Talley JJ; Welch MJ
J Nucl Med; 2002 Jan; 43(1):117-24. PubMed ID: 11801714
[TBL] [Abstract][Full Text] [Related]
16. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.
Riendeau D; Percival MD; Brideau C; Charleson S; Dubé D; Ethier D; Falgueyret JP; Friesen RW; Gordon R; Greig G; Guay J; Mancini J; Ouellet M; Wong E; Xu L; Boyce S; Visco D; Girard Y; Prasit P; Zamboni R; Rodger IW; Gresser M; Ford-Hutchinson AW; Young RN; Chan CC
J Pharmacol Exp Ther; 2001 Feb; 296(2):558-66. PubMed ID: 11160644
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and preliminary biological evaluation of new radioiodinated MMP inhibitors for imaging MMP activity in vivo.
Kopka K; Breyholz HJ; Wagner S; Law MP; Riemann B; Schröer S; Trub M; Guilbert B; Levkau B; Schober O; Schäfers M
Nucl Med Biol; 2004 Feb; 31(2):257-67. PubMed ID: 15013492
[TBL] [Abstract][Full Text] [Related]
18. In vivo expression of cyclooxygenase-1 in activated microglia and macrophages during neuroinflammation visualized by PET with 11C-ketoprofen methyl ester.
Shukuri M; Takashima-Hirano M; Tokuda K; Takashima T; Matsumura K; Inoue O; Doi H; Suzuki M; Watanabe Y; Onoe H
J Nucl Med; 2011 Jul; 52(7):1094-101. PubMed ID: 21680698
[TBL] [Abstract][Full Text] [Related]
19. In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators.
Henrotin Y; de Leval X; Mathy-Hartet M; Mouithys-Mickalad A; Deby-Dupont G; Dogné JM; Delarge J; Reginster JY
Inflamm Res; 2001 Aug; 50(8):391-9. PubMed ID: 11556519
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of COX-1/COX-2 selectivity and potency of a new class of COX-2 inhibitors.
Gierse J; Nickols M; Leahy K; Warner J; Zhang Y; Cortes-Burgos L; Carter J; Seibert K; Masferrer J
Eur J Pharmacol; 2008 Jun; 588(1):93-8. PubMed ID: 18457826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
